康诺亚宣布，公司NewCo合作企业Ouro Medicines已与吉利德科学签署并购协议，吉利德将通过并购方式收购Ouro Medicines，交易金额包括16.75亿美元首付款（可按惯例调整）和最高5亿美元里程碑付款，总交易金额可达21.75亿美元。根据并购协议，作为Ouro Medicines的股东，交易完成后康诺亚将获得约2.5亿美元首付款，以及最高约7000万美元的里程碑付款，总收入金额可达约3.2亿美元；同时，康诺亚对CM336/OM336的特许销售分层将由吉利德履行。交易完成后，康诺亚将不再持有Ouro Medicines股权。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.